Announcements Trials
Browse Landscape

Status

Completed 55Recruiting 33Unknown 18Terminated 13Active not recruiting 11Withdrawn 6Not yet recruiting 6Enrolling by invitation 4No longer available 3Available 2Approved for marketing 2

Sponsor Class

OTHER 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

Endocrine 3CNS 3Head & Neck 1

Conditions

Neuroendocrine Tumors 4Pheochromocytoma 3Neuroblastoma 3Carcinoid Tumor 3Paraganglioma 2Thyroid cancer, medullary 1Insulinoma 1Carcinoma, Medullary 1Adenoma, Islet Cell 1

Interventions

3-Iodobenzylguanidine 2pegfilgrastim 1fluorodopa F 18 1Vorinostat 1Potassium Iodide 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Pheochromocytoma × Endocrine × Clear all
NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡